Posted inGastroenterology news Oncology
Targeting MLCK1 May Separate Immune Checkpoint Inhibitor Colitis From Antitumour Benefit
A Gut study identifies MLCK1-driven epithelial barrier failure as a central mechanism in immune checkpoint inhibitor colitis and suggests epicatechin as a barrier-protective strategy that preserves antitumour efficacy in preclinical models.